BRCA2 and breast cancer: HR defects, e.g., due to inactivating mutations in BRCA1 and BRCA2 genes, are exploited in ovarian and breast cancer treatment, where single strand repair inhibitors (PARP inhibitors) as post-chemotherapy maintenance treatment show high efficacy in the HR-deficient subpopulation of patients.